Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis.

[1]  M. Relling,et al.  FUNCTIONAL CHARACTERIZATION OF ABCC2 PROMOTER POLYMORPHISMS AND ALLELE SPECIFIC EXPRESSION , 2012, The Pharmacogenomics Journal.

[2]  E. Pataraia,et al.  Lack of association between ABCC2 gene variants and treatment response in epilepsy. , 2012, Pharmacogenomics.

[3]  E. Poggiogalle,et al.  Mutational analysis of ABCC2 gene in two siblings with neonatal‐onset Dubin Johnson syndrome , 2010, Clinical genetics.

[4]  Barbara Zehnbauer,et al.  Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. , 2010, The Journal of molecular diagnostics : JMD.

[5]  S. Sookoian,et al.  Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. , 2009, The Journal of nutritional biochemistry.

[6]  A. Caliebe,et al.  Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol , 2008, Pharmacogenetics and genomics.

[7]  Hassane Izzedine,et al.  Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. , 2006, The Journal of infectious diseases.

[8]  C. Aquilante,et al.  Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults: A Pilot Study , 2006, Journal of acquired immune deficiency syndromes.

[9]  Michel Eichelbaum,et al.  Interindividual variability of canalicular ATP‐binding‐cassette (ABC)–transporter expression in human liver , 2006, Hepatology.

[10]  Ulrich Hoffmann,et al.  Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition , 2006, Expert opinion on drug metabolism & toxicology.

[11]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[12]  E. Hahn,et al.  Readmissions and adverse drug reactions in internal medicine: the economic impact , 2004, Journal of internal medicine.

[13]  C. J. Zheng,et al.  Drug ADME‐associated protein database as a resource for facilitating pharmacogenomics research , 2004 .

[14]  Y. Sugiyama,et al.  Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2 , 2004, Pharmaceutical Research.

[15]  S. Muallem,et al.  Identification and Functional Analysis of Two Novel Mutations in the Multidrug Resistance Protein 2 Gene in Israeli Patients with Dubin-Johnson Syndrome* , 2001, The Journal of Biological Chemistry.

[16]  B. Pomeranz,et al.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. , 1998, JAMA.

[17]  K. Kohno,et al.  Mutations in the Canalicular Multispecific Organic Anion Transporter (cMOAT) Gene, a Novel ABC Transporter, in Patients with Hyperbilirubinemia II/Dubin-Johnson Syndrome , 1998 .

[18]  P. Zimniak.  Dubin-Johnson and Rotor Syndromes: Molecular Basis and Pathogenesis , 1993, Seminars in liver disease.

[19]  E. Lyon,et al.  Characterization of 107 Genomic DNA Reference Materials for CYP 2 D 6 , CYP 2 C 19 , CYP 2 C 9 , VKORC 1 , and UGT 1 A 1 A GeT-RM and Association for Molecular Pathology Collaborative Project , 2010 .

[20]  S. Sookoian,et al.  Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. , 2008, Journal of hepatology.

[21]  H. Kroemer,et al.  Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex , 2007, The Pharmacogenomics Journal.

[22]  T. Uchiumi,et al.  Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. , 1999, American journal of human genetics.